303 related articles for article (PubMed ID: 27903862)
1. Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2.
Arenas-Ramirez N; Zou C; Popp S; Zingg D; Brannetti B; Wirth E; Calzascia T; Kovarik J; Sommer L; Zenke G; Woytschak J; Regnier CH; Katopodis A; Boyman O
Sci Transl Med; 2016 Nov; 8(367):367ra166. PubMed ID: 27903862
[TBL] [Abstract][Full Text] [Related]
2. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
[TBL] [Abstract][Full Text] [Related]
3. Development of a novel class of interleukin-2 immunotherapies for metastatic cancer.
Boyman O; Arenas-Ramirez N
Swiss Med Wkly; 2019 Jan; 149():w14697. PubMed ID: 30673115
[TBL] [Abstract][Full Text] [Related]
4. Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells.
Vazquez-Lombardi R; Loetsch C; Zinkl D; Jackson J; Schofield P; Deenick EK; King C; Phan TG; Webster KE; Sprent J; Christ D
Nat Commun; 2017 May; 8():15373. PubMed ID: 28497796
[TBL] [Abstract][Full Text] [Related]
5. Increasing the biological activity of IL-2 and IL-15 through complexing with anti-IL-2 mAbs and IL-15Rα-Fc chimera.
Votavova P; Tomala J; Kovar M
Immunol Lett; 2014; 159(1-2):1-10. PubMed ID: 24512738
[TBL] [Abstract][Full Text] [Related]
6. Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells.
Krieg C; Létourneau S; Pantaleo G; Boyman O
Proc Natl Acad Sci U S A; 2010 Jun; 107(26):11906-11. PubMed ID: 20547866
[TBL] [Abstract][Full Text] [Related]
7. Enhancing Dendritic Cell-based Immunotherapy with IL-2/Monoclonal Antibody Complexes for Control of Established Tumors.
Kim MT; Richer MJ; Gross BP; Norian LA; Badovinac VP; Harty JT
J Immunol; 2015 Nov; 195(9):4537-44. PubMed ID: 26408669
[TBL] [Abstract][Full Text] [Related]
8. An IL-2-grafted antibody immunotherapy with potent efficacy against metastatic cancer.
Sahin D; Arenas-Ramirez N; Rath M; Karakus U; Hümbelin M; van Gogh M; Borsig L; Boyman O
Nat Commun; 2020 Dec; 11(1):6440. PubMed ID: 33353953
[TBL] [Abstract][Full Text] [Related]
9. Administration of anti-CD25 mAb leads to impaired α-galactosylceramide-mediated induction of IFN-γ production in a murine model.
Rosalia RA; Štěpánek I; Polláková V; Šímová J; Bieblová J; Indrová M; Moravcová S; Přibylová H; Bontkes HJ; Bubeník J; Sparwasser T; Reiniš M
Immunobiology; 2013 Jun; 218(6):851-9. PubMed ID: 23182710
[TBL] [Abstract][Full Text] [Related]
10. Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity.
Onda M; Kobayashi K; Pastan I
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4575-4582. PubMed ID: 30760587
[TBL] [Abstract][Full Text] [Related]
11. Combinations of tumor-specific CD8+ CTLs and anti-CD25 mAb provide improved immunotherapy.
Ohmura Y; Yoshikawa K; Saga S; Ueda R; Kazaoka Y; Yamada S
Oncol Rep; 2008 May; 19(5):1265-70. PubMed ID: 18425386
[TBL] [Abstract][Full Text] [Related]
12. [Infusion of ex vivo expanded homologous CD4⁺;CD25⁺; regulatory T cells promotes the susceptibility to tumor in mice].
Guo T; Luo S; Xu J; Dai J; Liu Z; Gao X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 May; 30(5):466-70. PubMed ID: 24796739
[TBL] [Abstract][Full Text] [Related]
13. Stimulation of α7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro.
Wang DW; Zhou RB; Yao YM; Zhu XM; Yin YM; Zhao GJ; Dong N; Sheng ZY
J Pharmacol Exp Ther; 2010 Dec; 335(3):553-61. PubMed ID: 20843956
[TBL] [Abstract][Full Text] [Related]
14. Combined Cancer Immunotherapy Against Aurora Kinase A.
Kaštánková I; Poláková I; Dušková M; Šmahel M
J Immunother; 2016 May; 39(4):160-70. PubMed ID: 27070447
[TBL] [Abstract][Full Text] [Related]
15. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'.
Levin AM; Bates DL; Ring AM; Krieg C; Lin JT; Su L; Moraga I; Raeber ME; Bowman GR; Novick P; Pande VS; Fathman CG; Boyman O; Garcia KC
Nature; 2012 Mar; 484(7395):529-33. PubMed ID: 22446627
[TBL] [Abstract][Full Text] [Related]
16. Increased numbers and suppressive activity of regulatory CD25(+)CD4(+) T lymphocytes in the absence of CD4 engagement by MHC class II molecules.
Shen X; Niu C; König R
Cell Immunol; 2013 Apr; 282(2):117-28. PubMed ID: 23770721
[TBL] [Abstract][Full Text] [Related]
17. Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25.
Hannani D; Vétizou M; Enot D; Rusakiewicz S; Chaput N; Klatzmann D; Desbois M; Jacquelot N; Vimond N; Chouaib S; Mateus C; Allison JP; Ribas A; Wolchok JD; Yuan J; Wong P; Postow M; Mackiewicz A; Mackiewicz J; Schadendorff D; Jaeger D; Zörnig I; Hassel J; Korman AJ; Bahjat K; Maio M; Calabro L; Teng MW; Smyth MJ; Eggermont A; Robert C; Kroemer G; Zitvogel L
Cell Res; 2015 Feb; 25(2):208-24. PubMed ID: 25582080
[TBL] [Abstract][Full Text] [Related]
18. In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy.
Tomala J; Chmelova H; Mrkvan T; Rihova B; Kovar M
J Immunol; 2009 Oct; 183(8):4904-12. PubMed ID: 19801515
[TBL] [Abstract][Full Text] [Related]
19. INFα-2b inhibitory effects on CD4(+)CD25(+)FOXP3(+) regulatory T cells in the tumor microenvironment of C57BL/6 J mice with melanoma xenografts.
Yu Y; Huang R; Zong X; He X; Mo W
BMC Cancer; 2016 Jul; 16():397. PubMed ID: 27389040
[TBL] [Abstract][Full Text] [Related]
20. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells.
Rech AJ; Vonderheide RH
Ann N Y Acad Sci; 2009 Sep; 1174():99-106. PubMed ID: 19769742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
